DENVER, CO--(Marketwired - Apr 16, 2014) - Mountain High Acquisitions Corp. (
"Dr. Melamede is a visionary and a pioneer in the field of medicinal cannabis research, so we are greatly honored that he has agreed to join our team as Scientific Advisor," stated Mr. Alan Smith, President of Mountain High Acquisitions Corp. "His years of leading scientific research and cannabis advocacy have earned him a reputation as a vital industry source of knowledge, opinion, industry contacts, and inspiration. As our new Scientific Advisor, we are confident that he will be instrumental in helping us achieve our corporate objectives. In particular, his advice will be invaluable as we provide additional complementary services to current and future cannabis growing tenants and strategically develop our properties for use by the cannabis industry."
Dr. Robert Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede is the President of Cannabis Science, Inc. (
About Mountain High Acquisitions Corp. (MYHI)
Mountain High Acquisitions Corp. is a strategic real estate holding company whose primary focus is the acquisition and development of commercial properties to be leased and utilized by the marijuana industry. Mountain High's current portfolio includes three Colorado properties zoned for commercial marijuana cultivation: Isabelle, Madison, and Pueblo.
Disclaimer/Safe Harbor: This Mountain High Acquisitions Corp. news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all. The Company does not and will not grow, harvest, distribute, or sell cannabis or any substances that violate United States law or the Controlled Substances Act, nor does it intend to do so in the future.
- Health Care Industry